Inogen, Inc (NASDAQ:INGN) – Equities researchers at Leerink Swann increased their FY2017 EPS estimates for Inogen in a research report issued to clients and investors on Friday. Leerink Swann analyst D. Antalffy now anticipates that the medical technology company will post earnings per share of $1.17 for the year, up from their prior estimate of $1.07. Leerink Swann also issued estimates for Inogen’s Q4 2017 earnings at $0.21 EPS, Q4 2018 earnings at $0.29 EPS and FY2018 earnings at $1.23 EPS.

Inogen (NASDAQ:INGN) last announced its quarterly earnings data on Thursday, August 3rd. The medical technology company reported $0.38 EPS for the quarter, beating the Zacks’ consensus estimate of $0.28 by $0.10. The business had revenue of $64.10 million during the quarter, compared to the consensus estimate of $59.99 million. Inogen had a return on equity of 12.45% and a net margin of 10.36%. The business’s revenue for the quarter was up 17.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.25 earnings per share. TRADEMARK VIOLATION NOTICE: “FY2017 Earnings Estimate for Inogen, Inc Issued By Leerink Swann (NASDAQ:INGN)” was posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be read at https://www.americanbankingnews.com/2017/08/07/fy2017-earnings-estimate-for-inogen-inc-issued-by-leerink-swann-nasdaqingn.html.

INGN has been the topic of a number of other reports. Needham & Company LLC dropped their price target on shares of Inogen from $108.00 to $96.00 and set a “strong-buy” rating on the stock in a research note on Thursday, June 8th. BidaskClub downgraded shares of Inogen from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Sidoti assumed coverage on shares of Inogen in a research note on Tuesday, April 18th. They issued a “neutral” rating and a $79.00 price target on the stock. Zacks Investment Research downgraded shares of Inogen from a “hold” rating to a “sell” rating in a research note on Wednesday, May 10th. Finally, Stifel Nicolaus upped their price target on shares of Inogen from $65.00 to $75.00 and gave the stock a “hold” rating in a research note on Wednesday, May 10th. Three equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. Inogen has a consensus rating of “Buy” and a consensus price target of $91.60.

A number of institutional investors have recently bought and sold shares of the company. Ameritas Investment Partners Inc. acquired a new position in Inogen during the first quarter valued at approximately $109,000. Victory Capital Management Inc. boosted its stake in Inogen by 36.1% in the first quarter. Victory Capital Management Inc. now owns 1,729 shares of the medical technology company’s stock worth $134,000 after buying an additional 459 shares during the period. State of Alaska Department of Revenue boosted its stake in Inogen by 4.1% in the first quarter. State of Alaska Department of Revenue now owns 1,790 shares of the medical technology company’s stock worth $138,000 after buying an additional 70 shares during the period. Sei Investments Co. boosted its stake in Inogen by 38.1% in the second quarter. Sei Investments Co. now owns 1,606 shares of the medical technology company’s stock worth $153,000 after buying an additional 443 shares during the period. Finally, Jane Street Group LLC purchased a new stake in Inogen during the first quarter worth about $203,000.

In other Inogen news, Director Ray Benjamin M. Anderson sold 4,445 shares of the stock in a transaction on Thursday, May 18th. The shares were sold at an average price of $81.05, for a total transaction of $360,267.25. Following the transaction, the director now directly owns 4,445 shares of the company’s stock, valued at $360,267.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Matt Scribner sold 2,500 shares of the stock in a transaction on Tuesday, July 18th. The stock was sold at an average price of $94.21, for a total transaction of $235,525.00. Following the transaction, the executive vice president now directly owns 4,833 shares in the company, valued at $455,316.93. The disclosure for this sale can be found here. Insiders have sold 87,848 shares of company stock worth $7,831,966 over the last three months. Company insiders own 5.31% of the company’s stock.

Inogen Company Profile

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

Earnings History and Estimates for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.